Zacks' 7 Best Stocks for July, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

Mindray to Attend Medical Fair

by Zacks Equity Research

April 09, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Mindray Medical International Limited (MR - Analyst Report), a leading Chinese medical device manufacturer, recently revealed its intended participation in the 67th China International Medical Equipment Fair ("CMEF"). The event will take place between April 17, 2012 and April 20, 2012 in Shenzhen, China.

The company will showcase over 90 offerings from its three business lines. The broad segments are medical imaging, patient monitoring and life support as well as in-vitro diagnostic. Included among the exhibits are three latest offerings from the company, namely, the SynoVent E5 and E3 ventilators, the BS-2000 biochemistry analyzer and the DC-8 ultrasound system.

Mindray is a bellwether for the Chinese medical devices industry. The company has a large domestic sales infrastructure, which gives it better access to medium-sized county hospitals. In China, it beats other multinationals on price and defeats local players, who have cheaper products, on brand recognition.

In western markets, the company targets mid-market, price-sensitive customers. A key distinction with domestic competitors is that the majority of Mindray’s products have CE Mark and/or FDA clearance.

Mindray has a solid product pipeline. The company introduces about 10 new products each year. In fiscal 2011, it launched as many as 13 new products. New products contribute in a major way to the company’s revenues. The client base of the company is widely dispersed on a net revenues basis and is marked by low client concentration.

The medical device industry is characterized by quick product development, rapid technological advances, intense competition and a strong emphasis on proprietary products. The company has entered the premium segment globally where its competitive advantage is still evolving. Healthcare reform, in both China and the U.S., may reduce demand for Mindray’s products. Competition is fierce and leads to price erosion over time.

Mindray’s competitors, in different niche segments, include General Electric (GE - Analyst Report), Philips (PHG - Analyst Report) and Siemens (SI - Analyst Report), among a host of other players. Our recommendation is supported by a short-term Zacks #3 Rank (Hold).

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.